GADOBENATE DIMEGLUMINE
Adult Anaplastic (Malignant) Meningioma
University of Southern CaliforniaSmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Adult Anaplastic (Malignant) Meningioma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribociclib St. Jude Children's Research Hospital | Phase 1 | CC |
gsk1120212 St. Jude Children's Research Hospital | Phase 1 | CC |
Sonidegib St. Jude Children's Research Hospital | Phase 1 | CC |
FILGRASTIM St. Jude Children's Research Hospital | Phase 1 | CC |
Therapeutic Allogeneic Lymphocytes City of Hope Medical Center | Phase 1 | CC |
ONC 206 Jazz Pharmaceuticals | Phase 1 | CC |
rg4733 National Cancer Institute (NCI) | Phase 1 | C |
Gadobutrol University of Southern California | N/A | D |
Same molecule, other indications
GADOBENATE DIMEGLUMINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →